Respiratory distress syndrome is due to defective?

Explanation

## Correct Answer: B. Type 2 pneumocytes Respiratory distress syndrome (RDS), also called hyaline membrane disease in neonates, results from **defective type 2 pneumocytes** that fail to produce adequate surfactant. Type 2 pneumocytes are cuboidal cells comprising ~5% of the alveolar surface but occupying ~40% of alveolar volume. These cells synthesize, store (in lamellar bodies), and secrete pulmonary surfactant—a lipid-protein complex (90% lipid, 10% protein) essential for reducing alveolar surface tension. In premature infants (especially <28 weeks gestation), type 2 pneumocyte maturation is incomplete, resulting in surfactant deficiency. Without adequate surfactant, alveolar surface tension remains high, causing alveolar collapse (atelectasis) at end-expiration. This leads to ventilation-perfusion mismatch, hypoxemia, and the characteristic "ground-glass" appearance on chest X-ray with air bronchograms. The pathophysiology is not a problem with epithelial integrity, gas exchange capacity, or capillary function—it is specifically the **loss of surfactant production capacity** that defines RDS. Indian neonatal units manage RDS with exogenous surfactant replacement (beractant, poractant alfa) and mechanical ventilation, confirming the surfactant-deficiency mechanism. ## Why the other options are wrong **A. Bronchial mucosal epithelial cells** — Bronchial epithelium is not involved in RDS pathogenesis. Bronchial cells secrete mucus and are part of the conducting airway, not the gas-exchange unit. RDS is an alveolar disease affecting the respiratory zone, not the bronchial tree. This option confuses the anatomical site of pathology. **C. Type 1 pneumocytes** — Type 1 pneumocytes cover ~95% of alveolar surface and are responsible for gas exchange, not surfactant production. Although they are damaged secondarily in RDS (leading to increased permeability and hyaline membrane formation), they are not the primary defect. The primary defect is type 2 pneumocyte dysfunction and surfactant deficiency, not type 1 cell failure. **D. Alveolar capillary endothelial cells** — Capillary endothelial cells are responsible for maintaining the blood-gas barrier integrity. While they are damaged in RDS (contributing to pulmonary edema and hyaline membrane formation), this is a **secondary consequence** of surfactant deficiency and alveolar collapse, not the primary defect. The initial lesion is type 2 pneumocyte dysfunction. ## High-Yield Facts - **Type 2 pneumocytes** synthesize and secrete pulmonary surfactant; their defective function causes RDS in premature infants. - **Surfactant** is 90% lipid (DPPC predominant) and 10% protein; it reduces alveolar surface tension and prevents atelectasis. - **Fetal lung maturity** is assessed by lecithin-sphingomyelin (L:S) ratio >2:1 in amniotic fluid; indicates adequate type 2 pneumocyte maturation. - **Antenatal corticosteroids** (betamethasone, dexamethasone) accelerate type 2 pneumocyte maturation and reduce RDS incidence by ~50% in India. - **Exogenous surfactant** (beractant, poractant alfa) is the standard treatment; administered intratracheally within 6 hours of birth in Indian NICUs. ## Mnemonics **Type 2 = Surfactant + Stem cells** Type 2 pneumocytes are **cuboidal**, **few in number** (~5% surface), but **functionally critical**: they produce surfactant AND serve as progenitor cells for type 1 pneumocyte replacement. Remember: Type 2 = **Two jobs** (surfactant + regeneration). **RDS = Respiratory Distress from Surfactant deficiency** RDS occurs when surfactant is **absent or deficient**—think **premature birth** (immature type 2 pneumocytes). The classic triad: atelectasis + hypoxemia + hyaline membranes. Treat with exogenous surfactant replacement. ## NBE Trap NBE may pair "type 1 pneumocytes" with RDS to trap students who confuse the cell that is **damaged** (type 1, leading to hyaline membrane formation) with the cell that is **defective at baseline** (type 2, failing to produce surfactant). The primary defect is type 2 dysfunction, not type 1 damage. ## Clinical Pearl In Indian NICUs, antenatal corticosteroids given to mothers at risk of preterm delivery (24–34 weeks) are the single most effective intervention to reduce RDS incidence. Neonates born <28 weeks almost always require exogenous surfactant; those >34 weeks rarely develop RDS—this clinical gradient directly reflects the timeline of type 2 pneumocyte maturation and surfactant production capacity. _Reference: Guyton & Hall Textbook of Medical Physiology, Ch. 37 (Pulmonary Ventilation); Robbins & Cotran Pathologic Basis of Disease, Ch. 15 (Lung)_